Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis

被引:0
|
作者
Shankar, Bairavi [1 ]
Yanek, Lisa [2 ]
Jefferson, Artrish [1 ]
Jani, Vivek [1 ]
Brown, Emily [1 ]
Tsottles, Daniel [3 ]
Barranco, Jennifer [3 ]
Zampino, Serena [1 ]
Ranek, Mark [4 ]
Sharma, Kavita [4 ]
Polydefkis, Michael [3 ]
Vaishnav, Joban [4 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD USA
[4] Johns Hopkins Univ Hosp, Dept Cardiol, Baltimore, MD USA
来源
JACC: CARDIOONCOLOGY | 2024年 / 6卷 / 03期
关键词
cardiac amyloidosis; health care disparities; outcomes; transthyretin; HEART-FAILURE; HEREDITARY; THAOS;
D O I
10.1016/j.jaccao.2024.05.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with signi ficant mortality. The Val122Ile variant, highly prevalent in Black patients, portends poorer survival compared with other ATTR-CM subtypes. Although Val122Ile is biologically more aggressive, the contribution of race and socioeconomic status (SES) to disease outcomes in patients with ATTR-CM is unde fined. OBJECTIVES The aim of this study was to evaluate the impact of race and SES on clinical outcomes in patients with ATTR-CM.<br /> METHODS Patients with ATTR-CM who received care at Johns Hopkins Hospital between 2006 and 2022 were included. SES was assessed using area deprivation index (ADI). Associations of race and ADI with heart failure (HF) hospitalization and/or death were measured using multivariable logistic or Cox proportional hazards models.<br /> RESULTS Of 282 patients, 225 (80%) were men, and 129 (46%) were Black. Black vs White patients disproportionately constituted the highest ADI (most deprived) category (66% vs 28%; P 1 / 4 0.004), and Black patients were more likely to have HF hospitalization or death over 5 years compared with White patients (log -rank P < 0.001). Among those with ADI >25, Black patients had a signi ficantly greater hazard of HF hospitalization or death compared with White patients, independent of disease stage at diagnosis (HR: 2.77; 95% CI: 1.45-5.32; P 1 / 4 0.002).<br /> CONCLUSIONS Black patients with low SES may be at greater risk for underdiagnosis and adverse outcomes compared with White patients. Ongoing efforts are needed to improve outcomes in this subset of patients with ATTR-CM. (J Am Coll Cardiol CardioOnc 2024;6:454 -463) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页码:454 / 463
页数:10
相关论文
共 50 条
  • [1] Race And Socioeconomic Status Impact Diagnosis And Clinical Outcomes In Transthyretin Cardiac Amyloidosis
    Shankar, Bairavi
    Jefferson, Artrish
    Mckoy, Desirae
    Yanek, Lisa
    Jani, Vivek
    Ranek, Mark
    Sharma, Kavita
    Polydefkis, Michael
    Vaishnav, Joban
    [J]. JOURNAL OF CARDIAC FAILURE, 2024, 30 (01) : 283 - 284
  • [2] Prognostic impact of diagnosis of transthyretin cardiac amyloidosis
    Arana, X.
    Goena, C.
    Villanueva, I.
    Solla, I.
    Rengel, A.
    Manas, L.
    Rilo, I.
    Gomez, A.
    Querejeta, R.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 71 - 71
  • [3] Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype
    Driggin, Elissa
    Helmke, Stephen
    De Los Santos, Jeffeny
    Teruya, Sergio
    Guadalupe, Samantha
    Goldsmith, Jeff
    Maurer, Mathew S.
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (02): : 73 - 80
  • [4] Clinical Predictors of Mortality and Outcomes in Patients with Transthyretin Cardiac Amyloidosis
    Tsay, David
    Goldsmith, Jeff
    Maurer, Mathew
    [J]. JOURNAL OF CARDIAC FAILURE, 2013, 19 (08) : S50 - S50
  • [5] Multicenter Transthyretin Cardiac Amyloidosis Study Demonstrates Differences In Phenotype And Outcomes By Race
    Cavalier, Joanna S.
    Bhattacharya, Priyanka
    Patolia, Harsh
    Chandramouli, Shivram
    Sen, Sounok
    Karra, Ravi
    Maurer, Mathew
    Khouri, Michel
    [J]. JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 699 - 700
  • [6] Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
    Gillmore, Julian D.
    Maurer, Mathew S.
    Falk, Rodney H.
    Merlini, Giampaolo
    Damy, Thibaud
    Dispenzieri, Angela
    Wechalekar, Ashutosh D.
    Berk, John L.
    Quarta, Candida C.
    Grogan, Martha
    Lachmann, Helen J.
    Bokhari, Sabahat
    Castano, Adam
    Dorbala, Sharmila
    Johnson, Geoff B.
    Glaudemans, Andor W. J. M.
    Rezk, Tamer
    Fontana, Marianna
    Palladini, Giovanni
    Milani, Paolo
    Guidalotti, Pierluigi L.
    Flatman, Katarina
    Lane, Thirusha
    Vonberg, Frederick W.
    Whelan, Carol J.
    Moon, James C.
    Ruberg, Frederick L.
    Miller, Edward J.
    Hutt, David F.
    Hazenberg, Bouke P.
    Rapezzi, Claudio
    Hawkins, Philip N.
    [J]. CIRCULATION, 2016, 133 (24) : 2404 - +
  • [7] HEALTH AND ECONOMIC IMPACT OF THE CORRECT DIAGNOSIS OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN SPAIN
    Peral, C.
    Formiga, F.
    Garcia, P.
    Martin-Sanchez, J.
    Navarro-Ruiz, A.
    Tarilonte, P.
    Lopez, A.
    Rubio-Rodriguez, D.
    Rubio-Terres, C.
    [J]. VALUE IN HEALTH, 2020, 23 : S490 - S491
  • [8] Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain
    Formiga, Francesc
    Garcia-Pavia, Pablo
    Martin Sanchez, Francisco Javier
    Navarro-Ruiz, Andres
    Rubio-Terres, Carlos
    Peral, Carmen
    Tarilonte, Patricia
    Lopez-Ibanez de Aldecoa, Alejandra
    Rubio-Rodriguez, Dario
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1127 - 1133
  • [9] Impact of Socioeconomic Status and Race on Sepsis Epidemiology and Outcomes
    Minejima, Emi
    Wong-Beringer, Annie
    [J]. JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (01): : 194 - 209
  • [10] Are there predictor variables for the diagnosis of transthyretin cardiac amyloidosis?
    Goena, C.
    Arana, X.
    Villanueva, I.
    Solla, I.
    Rengel, A.
    Querejeta, R.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 859 - 859